A Phase 1, Open-Label, Multicenter Study of ADA-011 as Monotherapy and in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Adanate, Inc.
Start Date
June 28, 2023
End Date
January 31, 2028
Awarded By
Adanate, Inc.
Start Date
June 28, 2023
End Date
January 31, 2028